Business Wire - December 22, 2008
Fixed-dose combinations (FDCs) of prescription drugs can prove clinically useful where polypharmacy is required ù for example, in the management of HIV, asthma, and cardiometabolic disorders such as diabetes, dyslipidemia, and hypertension. These products also offer pharmaceutical companies a relatively easy and inexpensive way to bring new drugs to market. However, new surveys of 40 managed care organization (MCO) medical/pharmacy directors and more than 400 physicians, together with a detailed analysis of health plan formularies, show that payers and physicians have mixed opinions about these products. Get the Answers You Need to Shape Your Strategy.
By reducing the number of medication doses that a patient must take, FDCs offer greater patient convenience and may improve adherence. How important do physicians and payers consider these advantages? What other advantages are FDCs perceived to offer? What disadvantages do physicians and payers see in FDCs?
Companies planning to launch an FDC should not expect to command substantial price premiums over the price of the respective single agents. How do pricing trends vary by therapeutic area? How does the availability of generic versions of single agents infl uence the pricing of FDCs?
Pharmaceutical companies face substantial challenges in securing favorable coverage for FDCs. How does formulary status vary by drug class? What factors infl uence formulary positioning? What drug utilization management tools do MCOs apply to FDCs in each drug class?
Scope
* General drug benefit and coverage trends: key factors in reimbursement decision making; formulary design trends; copayment trends; cost-containment measures.
* HIV therapies: current therapies; pricing; formulary status; physician and MCO views.
* Asthma drugs: current therapies; pricing; formulary status; physician views.
* Cardiometabolic drugs (antidiabetics, antidyslipidemics, antihypertensives): current therapies; pricing; formulary status; physician and MCO views.
Key Topics Covered:
* Executive Summary
* Strategic Considerations
* Stakeholder Implications
* Overview
* General Drug Benefi t and Coverage Trends
* HIV Therapies
* Current Therapies
* Pricing
* Formulary Status
* Physician and Managed Care Organization Views
* Asthma Drugs
* Current Therapies * Pricing
* Formulary Status
* Physician Views
* Cardiometabolic Drugs
* Current Therapies
* Antidiabetic Drugs
* Dyslipidemia Agents
* Antihypertensive Agents
* Pricing
* Antidiabetic Drugs
* Dyslipidemia Agents
* Antihypertensive Agents
* Formulary Status
* Physician and Managed Care Organization Views
* Outlook and Implications for the Pharmaceutical Industry
Companies Mentioned:
* AstraZeneca
* Biovail
* Dey Laboratories
* DuPont
* Gilead
* Kos Pharmaceuticals
* Novartis
* Pfizer
* Sankyo
* Sanofi -Aventis
* Schwarz Pharma
* Takeda Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/98a1a9/pricing_and_rei mbu
Contacts
Laura Wood | Senior Manager | press@researchandmarkets.com | Fax from USA: 646-607-1907 | Fax from rest of the world: +353-1-481-1716
081222
BW081245
Copyright © 2008 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .